Skip to main content
SpringerLink
Log in

Amgen Canada Inc. is warning of the risk of atypical femoral fracture associated with use of the osteoporosis treatment, Prolia [denosumab].

  • News item
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. Ward-Able C.PROLIA (denosumab) - Association with the Risk of Atypical Femoral Fractures - For Health Professionals. Internet Document: [2 pages], 16 Nov 2012. Available from: URL: http://hc-sc.gc.ca

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Amgen Canada Inc. is warning of the risk of atypical femoral fracture associated with use of the osteoporosis treatment, Prolia [denosumab].. React. Wkly. 1430, 3 (2012). https://doi.org/10.2165/00128415-201214300-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128415-201214300-00005

Keywords

Search

Navigation